Clovis Oncology Inc. (CLVS) Jumped To A New High On Phase 3 Study Results

Clovis Oncology Inc. (CLVS) announced Monday morning that its Phase 3 trial of rucaparib successfully achieved the primary endpoint of improved progression-free survival in patients with ovarian cancer.

from RTT - Before the Bell http://ift.tt/2sO2p7R
via IFTTT